Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

NYU Langone offers vascular-targeted photodynamic therapy for localized prostate cancer

28.07.2010
NYU Langone Medical Center has begun a clinical trial offering vascular-targeted photodynamic therapy to patients with localized prostate cancer. This novel, minimally invasive procedure uses a light-activated drug to deliver light energy waves by way of laser fibers in order to destroy prostate cancer cells.

"This minimally invasive technique for localized prostate cancer offers the potential to destroy the cancer without making any incision or causing any potentially devastating sexual, urinary or reproductive side-effects," said Samir S. Taneja, MD, The James M. Neissa and Janet Riha Neissa Associate Professor of Urologic Oncology and director of the Division of Urologic Oncology at NYU Langone Medical Center and principal investigator for the national, multi-center clinical trial testing this technology. "This procedure only treats the cancerous part of the prostate gland, similar to how a lumpectomy might be done for breast cancer.

Photodynamic therapy is just one of the many personalized treatment options offered by the Smilow Comprehensive Prostate Cancer Center at NYU Langone Medical Center. The Center offers a wide range of the latest treatment options for prostate cancer including: open or robotic prostatectomy surgery, brachytherapy, external beam radiation therapy, cryotherapy and high-intensity focused ultrasound (HIFU), a focal therapy that uses high-energy sound waves to treat prostate cancer, now also in clinical trials at the medical center.

This Phase I/II photodynamic therapy trial is open to men diagnosed with localized prostate cancer -- determined by a needle biopsy and advanced imaging techniques -- who have chosen active surveillance, also known as "watchful-waiting. During the procedure, laser fibers are positioned over the prostate where cancer cells have been identified. Once in place, a photosensitizing drug called WST11 is administered to the patient intravenously and circulates throughout the blood stream for ten-minutes. The laser fibers are then activated to deliver a specific wavelength of light to the prostate for twenty-minutes. When the light comes into contact with the drug in circulation, the laser fibers destroy the blood vessels around the tumor shutting down the blood supply to the cancer. Patients are followed for a year after treatment with PSA tests after each visit and an MRI and needle biopsy performed at six months.

"Focal treatment of prostate cancer with techniques such as photodynamic therapy is an emerging paradigm since the over treatment of prostate cancer is a major concern for both physicians and patients," said Dr. Taneja who is also a member of the NYU Cancer Institute.

Recent European studies show photodynamic therapy successfully treats localized prostate cancer with minimal side effects. This study will investigate optimal dosage of the photosensitive drug and light-energy waves and measure outcomes of patients as well as long-term cancer control. Researchers believe the technology has the potential to treat any early stage prostate cancer as well as tumors in other organs of the body.

About NYU Langone Medical Center

NYU Langone Medical Center is one of the nation's premier centers of excellence in healthcare, biomedical research, and medical education. For over 170 years, NYU physicians and researchers have made countless contributions to the practice and science of health care. Today the Medical Center consists of NYU School of Medicine, including the Smilow Research Center, the Skirball Institute of Biomolecular Medicine, and the Sackler Institute of Graduate Biomedical Sciences; and the NYU Hospitals Center, including Tisch Hospital, a 705-bed acute-care general hospital, Rusk Institute of Rehabilitation Medicine, the first and largest facility of its kind, and NYU Hospital for Joint Diseases, a leader in musculoskeletal care, a Clinical Cancer Center and numerous ambulatory sites.

Lauren Woods | EurekAlert!
Further information:
http://www.nyumc.org

More articles from Medical Engineering:

nachricht Visualizing gene expression with MRI
23.12.2016 | California Institute of Technology

nachricht Illuminating cancer: Researchers invent a pH threshold sensor to improve cancer surgery
21.12.2016 | UT Southwestern Medical Center

All articles from Medical Engineering >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

New Study Will Help Find the Best Locations for Thermal Power Stations in Iceland

19.01.2017 | Earth Sciences

Not of Divided Mind

19.01.2017 | Life Sciences

Molecule flash mob

19.01.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>